![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GLB1 |
Gene summary for GLB1 |
![]() |
Gene information | Species | Human | Gene symbol | GLB1 | Gene ID | 2720 |
Gene name | galactosidase beta 1 | |
Gene Alias | EBP | |
Cytomap | 3p22.3 | |
Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | P16278 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2720 | GLB1 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.49e-09 | 4.47e-01 | -0.1954 |
2720 | GLB1 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.70e-02 | 3.09e-01 | -0.1464 |
2720 | GLB1 | HTA11_866_3004761011 | Human | Colorectum | AD | 3.41e-07 | 5.12e-01 | 0.096 |
2720 | GLB1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.32e-03 | 3.74e-01 | 0.294 |
2720 | GLB1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.33e-19 | 7.58e-01 | 0.3859 |
2720 | GLB1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.70e-05 | 3.48e-01 | 0.3005 |
2720 | GLB1 | A015-C-203 | Human | Colorectum | FAP | 2.81e-04 | -1.23e-01 | -0.1294 |
2720 | GLB1 | A002-C-201 | Human | Colorectum | FAP | 2.43e-02 | -1.42e-01 | 0.0324 |
2720 | GLB1 | A002-C-205 | Human | Colorectum | FAP | 1.03e-03 | -7.54e-02 | -0.1236 |
2720 | GLB1 | A015-C-006 | Human | Colorectum | FAP | 1.16e-02 | -1.01e-01 | -0.0994 |
2720 | GLB1 | A015-C-106 | Human | Colorectum | FAP | 1.03e-02 | -9.05e-02 | -0.0511 |
2720 | GLB1 | A002-C-114 | Human | Colorectum | FAP | 3.59e-03 | -1.13e-01 | -0.1561 |
2720 | GLB1 | A015-C-104 | Human | Colorectum | FAP | 1.34e-04 | -1.70e-01 | -0.1899 |
2720 | GLB1 | A002-C-016 | Human | Colorectum | FAP | 5.74e-05 | -1.45e-01 | 0.0521 |
2720 | GLB1 | A015-C-002 | Human | Colorectum | FAP | 1.82e-02 | -2.20e-01 | -0.0763 |
2720 | GLB1 | A002-C-116 | Human | Colorectum | FAP | 1.21e-05 | -1.27e-01 | -0.0452 |
2720 | GLB1 | A014-C-008 | Human | Colorectum | FAP | 1.26e-02 | -1.80e-01 | -0.191 |
2720 | GLB1 | A018-E-020 | Human | Colorectum | FAP | 3.65e-03 | -8.61e-02 | -0.2034 |
2720 | GLB1 | CRC-3-11773 | Human | Colorectum | CRC | 1.52e-02 | -6.37e-02 | 0.2564 |
2720 | GLB1 | LZE4T | Human | Esophagus | ESCC | 4.67e-04 | 2.13e-01 | 0.0811 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007266523 | Thyroid | ATC | protein localization to vacuole | 38/6293 | 67/18723 | 8.48e-05 | 6.33e-04 | 38 |
GO:009730528 | Thyroid | ATC | response to alcohol | 113/6293 | 253/18723 | 1.53e-04 | 1.06e-03 | 113 |
GO:003246511 | Thyroid | ATC | regulation of cytokinesis | 47/6293 | 92/18723 | 3.95e-04 | 2.39e-03 | 47 |
GO:190211713 | Thyroid | ATC | positive regulation of organelle assembly | 36/6293 | 67/18723 | 5.41e-04 | 3.13e-03 | 36 |
GO:199092813 | Thyroid | ATC | response to amino acid starvation | 28/6293 | 49/18723 | 6.01e-04 | 3.43e-03 | 28 |
GO:004408813 | Thyroid | ATC | regulation of vacuole organization | 26/6293 | 45/18723 | 7.43e-04 | 4.14e-03 | 26 |
GO:001605224 | Thyroid | ATC | carbohydrate catabolic process | 71/6293 | 154/18723 | 8.33e-04 | 4.57e-03 | 71 |
GO:00513027 | Thyroid | ATC | regulation of cell division | 80/6293 | 177/18723 | 8.54e-04 | 4.68e-03 | 80 |
GO:003280114 | Thyroid | ATC | receptor catabolic process | 17/6293 | 28/18723 | 2.97e-03 | 1.35e-02 | 17 |
GO:003419813 | Thyroid | ATC | cellular response to amino acid starvation | 25/6293 | 46/18723 | 3.00e-03 | 1.36e-02 | 25 |
GO:009732011 | Thyroid | ATC | plasma membrane tubulation | 13/6293 | 20/18723 | 4.03e-03 | 1.73e-02 | 13 |
GO:005138427 | Thyroid | ATC | response to glucocorticoid | 65/6293 | 148/18723 | 5.62e-03 | 2.28e-02 | 65 |
GO:003196027 | Thyroid | ATC | response to corticosteroid | 72/6293 | 167/18723 | 6.39e-03 | 2.55e-02 | 72 |
GO:200078513 | Thyroid | ATC | regulation of autophagosome assembly | 21/6293 | 39/18723 | 7.26e-03 | 2.86e-02 | 21 |
GO:19011363 | Thyroid | ATC | carbohydrate derivative catabolic process | 73/6293 | 172/18723 | 9.43e-03 | 3.47e-02 | 73 |
GO:00421493 | Thyroid | ATC | cellular response to glucose starvation | 24/6293 | 48/18723 | 1.37e-02 | 4.77e-02 | 24 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa00052 | Colorectum | FAP | Galactose metabolism | 12/1404 | 32/8465 | 3.61e-03 | 1.53e-02 | 9.29e-03 | 12 |
hsa000521 | Colorectum | FAP | Galactose metabolism | 12/1404 | 32/8465 | 3.61e-03 | 1.53e-02 | 9.29e-03 | 12 |
hsa0414222 | Esophagus | ESCC | Lysosome | 102/4205 | 132/8465 | 5.11e-11 | 7.13e-10 | 3.65e-10 | 102 |
hsa006003 | Esophagus | ESCC | Sphingolipid metabolism | 36/4205 | 53/8465 | 5.41e-03 | 1.36e-02 | 6.99e-03 | 36 |
hsa0414232 | Esophagus | ESCC | Lysosome | 102/4205 | 132/8465 | 5.11e-11 | 7.13e-10 | 3.65e-10 | 102 |
hsa0060012 | Esophagus | ESCC | Sphingolipid metabolism | 36/4205 | 53/8465 | 5.41e-03 | 1.36e-02 | 6.99e-03 | 36 |
hsa041424 | Liver | Cirrhotic | Lysosome | 68/2530 | 132/8465 | 1.34e-07 | 1.97e-06 | 1.21e-06 | 68 |
hsa0414211 | Liver | Cirrhotic | Lysosome | 68/2530 | 132/8465 | 1.34e-07 | 1.97e-06 | 1.21e-06 | 68 |
hsa041422 | Liver | HCC | Lysosome | 100/4020 | 132/8465 | 2.32e-11 | 4.31e-10 | 2.40e-10 | 100 |
hsa00511 | Liver | HCC | Other glycan degradation | 15/4020 | 18/8465 | 1.96e-03 | 6.91e-03 | 3.84e-03 | 15 |
hsa00600 | Liver | HCC | Sphingolipid metabolism | 34/4020 | 53/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 34 |
hsa041423 | Liver | HCC | Lysosome | 100/4020 | 132/8465 | 2.32e-11 | 4.31e-10 | 2.40e-10 | 100 |
hsa005111 | Liver | HCC | Other glycan degradation | 15/4020 | 18/8465 | 1.96e-03 | 6.91e-03 | 3.84e-03 | 15 |
hsa006001 | Liver | HCC | Sphingolipid metabolism | 34/4020 | 53/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 34 |
hsa041425 | Oral cavity | OSCC | Lysosome | 87/3704 | 132/8465 | 1.97e-07 | 1.35e-06 | 6.86e-07 | 87 |
hsa006002 | Oral cavity | OSCC | Sphingolipid metabolism | 33/3704 | 53/8465 | 5.00e-03 | 1.20e-02 | 6.13e-03 | 33 |
hsa0414212 | Oral cavity | OSCC | Lysosome | 87/3704 | 132/8465 | 1.97e-07 | 1.35e-06 | 6.86e-07 | 87 |
hsa0060011 | Oral cavity | OSCC | Sphingolipid metabolism | 33/3704 | 53/8465 | 5.00e-03 | 1.20e-02 | 6.13e-03 | 33 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GLB1 | SNV | Missense_Mutation | c.1336N>C | p.Ala446Pro | p.A446P | P16278 | protein_coding | tolerated(0.2) | possibly_damaging(0.897) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | |
GLB1 | SNV | Missense_Mutation | novel | c.302N>G | p.Asp101Gly | p.D101G | P16278 | protein_coding | tolerated(0.07) | possibly_damaging(0.863) | TCGA-E9-A245-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
GLB1 | SNV | Missense_Mutation | c.1628N>T | p.Ser543Leu | p.S543L | P16278 | protein_coding | tolerated(0.14) | possibly_damaging(0.543) | TCGA-GM-A2DF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR | |
GLB1 | SNV | Missense_Mutation | c.592N>C | p.Asp198His | p.D198H | P16278 | protein_coding | deleterious(0.05) | possibly_damaging(0.9) | TCGA-LL-A5YO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
GLB1 | insertion | Frame_Shift_Ins | novel | c.1526_1527insCG | p.Trp509CysfsTer92 | p.W509Cfs*92 | P16278 | protein_coding | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
GLB1 | insertion | Frame_Shift_Ins | novel | c.1524_1525insATGGGGGAAAGGGAATCTTCCCACAT | p.Trp509MetfsTer100 | p.W509Mfs*100 | P16278 | protein_coding | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
GLB1 | insertion | Frame_Shift_Ins | novel | c.1909_1910insGTGTACATAGTATGGTATATCT | p.Thr637SerfsTer29 | p.T637Sfs*29 | P16278 | protein_coding | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | ||
GLB1 | deletion | Frame_Shift_Del | novel | c.237delN | p.Ile80SerfsTer41 | p.I80Sfs*41 | P16278 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
GLB1 | SNV | Missense_Mutation | novel | c.790N>A | p.Leu264Met | p.L264M | P16278 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-EA-A3Y4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
GLB1 | SNV | Missense_Mutation | c.423N>T | p.Glu141Asp | p.E141D | P16278 | protein_coding | tolerated(0.18) | benign(0.006) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |